BEIJING (Reuters) - A scandal over faulty vaccines in China has sparked anger on social media, underscoring the difficulties regulators face in rebuilding trust after years of food and drug safety scares.
The incident is a major blow for Beijing’s efforts to push domestically made vaccines and for China’s drug regulator, which has been struggling to clean up the world’s second-biggest drug industry.
Worried parents trying to ascertain if their children had been administered faulty vaccines led to the topic becoming the second most watched at the weekend on the Weibo social media site, with details widely shared on the WeChat messaging app.
“If the state does not protect its citizens, how can we love our country?” asked one Weibo user, while another lamented, “Looking at the news, I don’t dare to have an injection.”
The scandal erupted a week ago, after major vaccine maker Changsheng Biotechnology Co was found to have violated standards in making rabies vaccine for humans.
The regulator ordered it to halt production and recall all its vaccines, the company said in a statement.
On Thursday, however, it told the stock exchange that authorities in its base in northeastern Jilin province were fining it over substandard production, uncovered in 2017, of a DPT vaccine to combat diphtheria, pertussis and tetanus (DPT).
The defective vaccine might not confer immunity but would not affect human safety, provincial authorities had said in November, implicating another company, Wuhan Institute of Biological Products, in substandard DPT vaccines.
Reuters’ calls to Changsheng’s headquarters on Sunday went unanswered.
The Food and Drug Administration said in a statement on Sunday evening that its investigation had found that Changsheng fabricates production records and product inspection records, and arbitrarily changes process parameters and equipment, “serious violations” of the law.
It said the agency was investigating the company and suspected crimes would be handled by the public security department, adding that all vaccine producers would be inspected and any violations would be dealt with seriously.
In a stock exchange statement on Sunday, the company said its suspension of rabies vaccine production would have a significant impact on its finances and that some regional disease control agencies had suspended some of its other vaccines.
The latest problems come a little more than two years after police in northern Shandong province said they had uncovered the illegal sale of vaccines worth nearly $90 million.
Last week China’s Zhejiang Huaihai Pharmaceutical said it was recalling a heart drug sold in the United States after the European Medicines Agency found that it was tainted with an impurity linked to cancer.
The Changsheng scandal will hit confidence in domestic vaccines by rekindling safety concerns over products for children, a challenge state media highlighted.
“Vaccines directly concern the health of children and are related to life,” the state-run Global Times said in a commentary. “Every negative news item in this area will make all of society look at it.”
Changsheng’s shares fell the maximum limit of 10 percent on Friday, to stand at 14.5 yuan ($2.14). They have lost 40 percent of their value since July 13.
($1=6.7659 Chinese yuan renminbi)
Reporting by Dominique Patton; Additional reporting by Zhou Jianfeng; Editing by Clarence Fernandez and David Goodman
Our Standards: The Thomson Reuters Trust Principles.